Send the following on WhatsApp
Continue to ChatSanofi, GSK tout 72% Omicron efficacy in PhIII trial of next-gen, bivalent shot — with an eye to year-end rollout https://invesbrain.com/sanofi-gsk-tout-72-omicron-efficacy-in-phiii-trial-of-next-gen-bivalent-shot-with-an-eye-to-year-end-rollout/